Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized 5-period crossover, double-blind, placebo-controlled design phase 1 trial to assess the safety, tolerability and dose-response of N-N-dimethyltryptamine, including an assessment of the difference between infusion conditions

Next Previous
Trial Profile

A randomized 5-period crossover, double-blind, placebo-controlled design phase 1 trial to assess the safety, tolerability and dose-response of N-N-dimethyltryptamine, including an assessment of the difference between infusion conditions

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs N-N-dimethyltryptamine (Primary)
  • Indications Substance-related disorders
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 12 Jan 2026 According to Definium Therapeutics media release, MindMed is now called as Definium Therapeutics.
  • 03 Aug 2021 New trial record
  • 28 Jul 2021 According to a Mindmed media release, this trial is being conducted as an investigator-initiated study by Dr. Matthias Liechti as part of MindMed ongoing collaboration with the UHB Liechti Lab. The Phase 1 clinical trial has received all necessary regulatory approvals in Switzerland and subject enrollment has been initiated.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top